Loading...
XNAS
NBIX
Market cap15bUSD
Dec 05, Last price  
155.51USD
1D
0.84%
1Q
7.92%
Jan 2017
301.83%
Name

Neurocrine Biosciences Inc

Chart & Performance

D1W1MN
XNAS:NBIX chart
P/E
45.30
P/S
6.56
EPS
3.43
Div Yield, %
—
Shrs. gr., 5y
1.61%
Rev. gr., 5y
24.48%
Revenues
2.36b
+24.81%
123,889,00039,234,0001,224,0003,975,0002,953,00033,501,00077,413,00053,140,0002,919,000019,769,00015,000,000161,626,000451,240,000788,100,0001,045,900,0001,133,500,0001,488,700,0001,887,100,0002,355,300,000
Net income
341m
+36.68%
-22,191,000-107,205,000-207,299,000-88,613,000-51,038,000-7,968,00037,571,0005,025,000-46,090,000-60,542,000-88,929,000-141,090,000-142,542,00021,111,00037,000,000407,300,00089,600,000154,500,000249,700,000341,300,000
CFO
595m
+52.71%
-30,794,000-99,334,000-59,334,000-74,173,000-53,095,00049,943,000-681,000-35,294,000-29,607,000-47,140,000-37,997,000-106,181,000-94,331,000101,364,000152,054,000228,500,000256,500,000339,400,000389,900,000595,400,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL – Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
URL
https://www.neurocrine.com/
IPO date
May 23, 1996
Employees
1,350
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT